BG
RPRX

BlackRock Group’s Repros Therapeutics Inc. RPRX Stock Holding History

BlackRock Group’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-3,847
Closed -$68K – 2963
2014
Q1 		$68K Hold
3,847
– – ﹤0.01% 2611
2013
Q4 		$70K Hold
3,847
– – ﹤0.01% 2523
2013
Q3 		$103K Buy
+3,847
New +$82.4K ﹤0.01% 2599

Other funds holding RPRX

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

BlackRock Group's RPRX Position: Q2 2014 in Review

BlackRock Group sold out of Repros Therapeutics Inc. (RPRX) in Q2 2014, closing a stake of 3,847 shares — an estimated $68K sold.

BlackRock Group first reported a position in RPRX in Q3 2013 and held it in 3 quarters. The position peaked at $103K in Q3 2013. 77 funds tracked by Wall St. Rank hold RPRX as of Q2 2014.

  • BlackRock Group reported no remaining Repros Therapeutics Inc. position as of Q2 2014 after selling out during the quarter.
  • BlackRock Group sold 3,847 Repros Therapeutics Inc. shares in Q2 2014, an estimated $68K.
  • BlackRock Group first reported a position in Repros Therapeutics Inc. in Q3 2013 and held it in 3 quarters.
  • BlackRock Group's Repros Therapeutics Inc. position peaked at $103K in Q3 2013.
  • 77 funds tracked by Wall St. Rank held Repros Therapeutics Inc. as of Q2 2014.

Based on BlackRock Group's 13F filing for Q2 2014, filed 6 Aug 2014.